Please ensure Javascript is enabled for purposes of website accessibility

Why Fulgent Genetics Stock Temporarily Soared 31% Today

By Keith Speights - Mar 5, 2021 at 10:13AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors loved the company's fourth-quarter update but are concerned the growth could stall.

What happened

Shares of Fulgent Genetics (FLGT 3.78%) soared nearly 31% at one point Friday morning. However, the stock was up only 5% as of 11 a.m. EST. 

That huge, albeit temporary, gain stemmed from Fulgent's fourth-quarter update after the market close on Thursday. The genetic testing company reported revenue of $295 million with adjusted earnings of $167.5 million, or $6.20 per share. Both top- and bottom-line results represented huge improvements from the prior-year period and trounced Wall Street consensus estimates. Fulgent also provided 2021 guidance that projects 90% revenue growth this year.

DNA with a light shining on it

Image source: Getty Images.

So what

Fulgent delivered jaw-dropping growth. It blew past analyst expectations. The company's guidance was terrific. It's understandable why shares would jump as they did earlier today. But why did the healthcare stock give up most of its gains? It's probably because investors aren't convinced the growth is sustainable.

Most of Fulgent's tremendous revenue increase came from its COVID-19 testing business. Based on the company's guidance, this business should enjoy strong demand in 2021. However, there's a big question as to how long it will last.

As COVID-19 vaccines become more widely available, the pandemic could come to an end. While investors are excited about Fulgent's Q4 results, many of them probably also worry that the company's growth could taper off dramatically in the not-too-distant future.

Now what

One key thing to watch with Fulgent going forward is the growth in its non-COVID-19 business. The company said that its non-COVID-19 genetic testing revenue jumped 43% year over year in Q4. 

It's also possible that concerns about a steep decline in COVID-19 testing could be premature. The emergence of new coronavirus variants could mean that Fulgent Genetics' COVID-19 revenue will remain strong for a long time to come.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Fulgent Genetics, Inc. Stock Quote
Fulgent Genetics, Inc.
$56.79 (3.78%) $2.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.